51 results
6-K/A
EX-99.5
OBSVF
ObsEva SA
13 Oct 21
ObsEva Announces Relationship with Syneos Health to Commercialize Linzagolix
5:24pm
the accuracy of which has yet to be determined by the Company or which is the subject of an ongoing investigation or inquiry; provided that the Company takes … all action as necessary to as expeditiously as possible make such determination and conclude such investigation or inquiry.
b. “Effectiveness Deadline
6-K
EX-99.5
OBSVF
ObsEva SA
13 Oct 21
ObsEva Announces Relationship with Syneos Health to Commercialize Linzagolix
9:27am
the accuracy of which has yet to be determined by the Company or which is the subject of an ongoing investigation or inquiry; provided that the Company takes … all action as necessary to as expeditiously as possible make such determination and conclude such investigation or inquiry.
b. “Effectiveness Deadline
6-K
EX-99.2
OBSVF
ObsEva SA
10 Dec 20
Current report (foreign)
6:03am
products that are under clinical investigation and which have not yet been approved for marketing by the U.S. Food and Drug Administration
6-K
EX-1.1
OBSVF
ObsEva SA
22 Jun 18
ObsEva Announces Launch of ProposedFollow-on Public Offering
4:06pm
and shall be responsible for making its own independent investigation and appraisal of the transactions contemplated hereby, and neither … notice of any claim, action, suit, proceeding, hearing, enforcement, investigation, arbitration or other action from the Applicable Regulatory
6-K
EX-99.2
OBSVF
ObsEva SA
16 Nov 20
ObsEva SA Reports Positive Topline Results of the PROLONG Proof-of-Concept Trial of Ebopiprant (OBE022) for Treatment of Preterm Labor
6:39am
of an offer to buy any securities. This presentation concerns products that are under clinical investigation and which have not yet been approved for marketing
6-K
EX-1.1
59qawdm xy
8 Sep 20
ObsEva Announces $20.0 Million Underwritten Offering and Concurrent Private Placement
7:40am
6-K/A
EX-99.2
sl3yfq5d50
13 Oct 21
ObsEva Announces Relationship with Syneos Health to Commercialize Linzagolix
5:24pm
6-K
EX-99.3
dq1hzkl0
28 Jan 22
ObsEva Announces Corporate Updates
5:16pm
10-K
EX-10.20
pvxvugsix40bepoqj22x
31 Mar 23
Annual report
4:01pm
6-K
EX-99.2
7bccgg3
10 Dec 19
ObsEva Announces Positive Results from Uterine Fibroids Phase 3 Study (PRIMROSE 2) of Linzagolix
12:00am
F-3
bbhqlwtga ata9k
7 Aug 19
Shelf registration (foreign)
8:24am
6-K
EX-1.1
eochdj ykoipuf0nccn
5 Mar 21
Current report (foreign)
8:15am
6-K/A
EX-99.1
z2cay8 r7s84sx4
19 Jan 21
Current report (foreign) (amended)
6:25am
6-K
EX-99.1
jntmb60boy4vlmy
7 Jul 20
Current report (foreign)
3:39pm
6-K
EX-99.1
x3afq3ji nar0l7n6cn9
13 Jan 21
Current report (foreign)
4:00pm
6-K
EX-99.2
cib6 tpk87s
13 Oct 21
ObsEva Announces Relationship with Syneos Health to Commercialize Linzagolix
9:27am
F-3
EX-4.2
t1ze9gd6 mx3sw3lr6cc
7 Aug 19
Shelf registration (foreign)
8:24am
F-3
EX-4.2
9wxtp zw7c
9 Dec 22
Shelf registration (foreign)
7:06am
6-K
EX-99.1
12iy7pby
30 Mar 18
Current report (foreign)
12:00am
F-3
mpdqqbu 1c59z
9 Dec 22
Shelf registration (foreign)
7:06am